Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of effectiveness of tocilizumab in treating rheumatoid arthritis patients with high versus low comorbidity burden and in obese versus nonobese: The US Corrona RA registry study

Trial Profile

Comparison of effectiveness of tocilizumab in treating rheumatoid arthritis patients with high versus low comorbidity burden and in obese versus nonobese: The US Corrona RA registry study

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Tocilizumab (Primary) ; Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2018 Results assessing the effectiveness of tocilizumab in treating rheumatoid arthritis patients with high vs low comorbidity burden (n=770) and in obese vs nonobese patients (n=805), presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 17 Jul 2018 New trial record
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top